Why the study?
Ivabradine is a promising approach to improve outcomes in HFrEF either alone or with beta-blockers, motivating a review of current knowledge and its effects on HF outcomes.
Ivabradine is an effective adjunctive therapy to reduce hospitalizations in HFrEF patients who remain symptomatic with a heart rate ≥ 70 bpm despite maximally tolerated beta-blocker therapy.
May support reducing HFrEF readmissions with HR ≥70 bpm; hypothesis-generating and requires prospective RCTs.
Heart failure (HF) is the fourth-most frequent cause of death and remains a challenge for public health. Therapy goals for HF with reduced ejection fraction (HFrEF) are the improvement in the quality of life, prolonged survival, a reduction of signs and symptoms, and the prevention of hospitalization. Angiotensin-converting enzyme inhibitors, beta-blockers, and mineralocorticoid receptor antagonists are the treatments of choice for HFrEF. Although ivabradine is not available in all countries, it is likely a new promising approach to improve outcomes in patients with HFrEF, either alone or with beta-blockers. Here, we review the current knowledge about ivabradine in HFrEF and assess its effect on outcomes in HF.
No takes yet. Share an insight, caveat, or question.
Sattar et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: